Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUST
2024-519347-15-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of Lu-PNT2002 in prostate cancer (PCa) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Proportion of men with PSA progression at 12 months. Planned start Jan 2025; status: authorised.
02
Drugs
Lu-PNT2002
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-519347-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519347-15-00.